Clinical trials: Cisplatin, completed
Lymphoma
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00005601
- Testing
- rituximab, cisplatin, cytarabine
- Where
- 21 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer, Non Small Cell Lung Carcinoma
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
The trial investigates the feasibility and efficacy of targeting Non-Small Cell Lung Cancer (NSCLC) "driven" by epigenetic changes.
- Conditions
- Lung Cancer, Non Small Cell Lung Carcinoma, Hypermethylation
- Trial name
- NCT01209520
- Testing
- Cisplatin, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Miami
Adrenocortical Carcinoma
Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma
The trial is a phase II trial in adrenocortical carcinoma (ACC), a rare malignancy with poor prognosis. It will provide results leading to the establishment of the effect of the included drugs.
- Trial name
- NCT00324012
- Testing
- cisplatin, taxotere
- Where
- Denmark
- Volunteers
- 19 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Lung Cancer
Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with surgery may kill more tumor cells.
- Trial name
- NCT00003231
- Testing
- cisplatin, docetaxel, surgical procedure
- Where
- 9 sites in Switzerland
- Volunteers
- 40 people
- Sponsor
- Swiss Cancer Institute
Head and Neck Neoplasms, Hearing Disorder
Hearing Loss and the Effects of Statin Drugs in People With Head and Neck Squamous Cell Carcinoma Treated With Cisplatin Chemoradiation
Background: Cisplatin is a chemotherapy drug. It is used to treat head and neck squamous cell carcinoma (HNSCC) and other cancers. It can cause hearing loss for some people.
- Conditions
- Head and Neck Neoplasms, Hearing Disorder, Hyperlipidemia
- Trial name
- NCT03225157
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
Esophageal Neoplasms
Study Comparing Radiochemotherapy With Folfox 4 Regimen or 5FU-Cisplatin in Patients With Inoperable Esophageal Cancer
The primary objectives of this study are to assess the feasibility (completion of full treatment) in both arms and to assess endoscopic complete response rate in both arms.
- Trial name
- NCT00160030
- Testing
- FOLFOX 4, 5-FU / Cisplatin
- Where
- France
- Volunteers
- 97 people
- Sponsor
- Sanofi
Stomach Neoplasms
Docetaxel in Locally Advanced Gastric Adenocarcinoma
Study objectives: To determine Ro resection rate of Docetaxel, cisplatin and fluorouracil combination for the treatment of neoadjuvant gastric carcinoma.
- Trial name
- NEOTAX (NCT00343239)
- Testing
- Docetaxel, Cisplatin, Fluorouracil
- Where
- Turkey (Türkiye)
- Volunteers
- 59 people
- Sponsor
- Sanofi
Metastatic Melanoma
Taxotere/Temodar/Cisplatin Study in Melanoma Patients
Primary Objective: 1. To determine the maximum tolerated dose of chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma. Secondary Objectives: 1.
- Trial name
- NCT00527761
- Testing
- Cisplatin, Docetaxel, Temodar
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Pancreatic Ductal Adenocarcinoma
Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer
This study will evaluate the effects of the ketogenic diet in patients with metastatic pancreatic cancer while receiving chemotherapy.
- Trial name
- NCT04631445
- Testing
- Ketogenic Diet
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Translational Drug Development
Solid Tumor
Effect of Refnot on Immunity in Cancer Patients
The study was planned to include disseminated patients with various solid tumors (melanoma, soft tissue sarcoma, breast cancer, colon cancer, etc.).
- Trial name
- R-2 (NCT05898451)
- Testing
- Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T), Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T) and chemotherapy
- Volunteers
- 55 people
- Sponsor
- Refnot-Pharm Ltd
Head and Neck Squamous Cell Carcinoma
TRACE: Tirapazamine-Radiation And Cisplatin Evaluation
The trial will compare the efficacy and safety of concomitant chemoradiation with tirapazamine, cisplatin and radiation versus cisplatin and radiation.
- Trial name
- TRACE (NCT00174837)
- Testing
- Tirapazamine, Cisplatin
- Where
- 17 sites in United States, Argentina and 15 more
- Volunteers
- 317 people
- Sponsor
- Sanofi
Head and Neck Squamous Cell Carcinoma
Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC
This study evaluates the efficacy of the new docetaxel-cisplatin-cetuximab regimen (TPEx) versus the standard platinum-5FU-cetuximab EXTREME regimen as a first-line treatment in recurrent and/or metastatic HNSCC.
- Trial name
- TPExtreme (NCT02268695)
- Testing
- Cisplatin, 5-Fluorouracile, Docetaxel
- Where
- 17 sites in France, Germany and 1 more
- Volunteers
- 541 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Stage III Bladder Cancer, Stage IV Bladder Cancer
Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium
Randomized phase III trial to compare the effectiveness of immediate adjuvant chemotherapy with that of adjuvant chemotherapy given when the cancer returns in treating patients who have undergone a radical cystectomy for stage…
- Conditions
- Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
- Trial name
- NCT00028756
- Testing
- doxorubicin hydrochloride, gemcitabine hydrochloride, vinblastine sulfate
- Volunteers
- 285 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Multiple Myeloma
2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE
This study is being done in an attempt to improve the remission rate and the survival time for subjects with high-risk myeloma. It is hoped that by giving higher doses of commonly used chemotherapy drugs and by giving courses…
- Trial name
- NCT00577512
- Testing
- DTPACE
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Arkansas
Non-small Cell Lung Cancer
Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)
Stage IIIA non-small cell lung cancers comprising a mediastinal ganglionic invasion N2 account for 20 to 30% of the NSCLCs. They are almost always potentially resectable, but the results obtained by surgery alone or surgery…
- Trial name
- NCT00198367
- Testing
- Cisplatin-Gemzar, Cisplatin-Navelbine-Radiotherapy, Carboplatin-Taxol-Radiotherapy
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, and gemcitabine, work in different ways to stop the growth of tumor…
- Trial name
- NCT00623064
- Testing
- cisplatin, gemcitabine hydrochloride, lapatinib ditosylate
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Ovarian Cancer
A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer
Ovarian cancer is the most lethal gynecological cancer and the 5th leading cause of cancer death in women. Platinum chemotherapy has been widely adopted as a standard treatment for advanced ovarian cancer, the response rates in…
- Trial name
- NCT03989336
- Testing
- Manganese Chloride, nab-paclitaxel, Platinum chemotherapy
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Chinese PLA General Hospital
Brain and Central Nervous System Tumors
Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
Drugs used in chemotherapy, such as vincristine, cisplatin, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00085202
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 416 people
- Sponsor
- St. Jude Children's Research Hospital
Prostate Cancer
Cisplatin in Castration Resistant Prostate Cancer
It is hypothesized that treatment with cisplatin will reverse emerging refractoriness to enzalutimide in patients with CRPC by affecting AR function.
- Trial name
- NCT03275857
- Testing
- Cisplatin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Rochester
Nasopharyngeal Carcinoma
Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
Patients will be treated with pembrolizumab after concurrent chemoradiotherapy with cisplatin. Patients will be treated with up to 17 cycles (approximately 1 year) of pembrolizumab until disease progression or recurrence
- Trial name
- NCT04227509
- Testing
- Pembrolizumab
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Seoul National University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.